| Literature DB >> 33354570 |
Yi Zheng1, Yage Fan2, Yan Zeng3, Shiyu Liu2, Limin Gao4.
Abstract
The aim of this study is to reveal the certain human papillomavirus (HPV) genotype distribution between cervical cancer and esophageal cancer in the both high-incidence geographic regions. For this study, we collected and detected the infection of HPV in 120 paraffin-embedded esophageal tissues and 152 paraffin-embedded cervical tissues, respectively. The esophageal tissues include 40 normal epithelium (ENOR), 26 dysplasia (DYS), and 54 invasive squamous cell carcinoma (ESCC). The cervical tissues consisted of 40 normal epithelium (CNOR), 53 intraepithelial neoplasia (CIN), and 59 invasive squamous cell carcinoma (CSCC). Both esophageal and cervical tissues collected in this study came from the same area, in which both the ESCC and CSCC were in high incidence, Xinjiang province, China. HPV GenoArray test kits were served to analyze the HPV infection. The result shows that among the 59 CSCC tissues, the total infection rate of HPV was 98.3% (58/59). The positive rate of HPV-16 infection was 63.8% (37/58). It indicated that HPV-16 is the most common infection among all of the high-risk HPV. The multiple infection rate was 19.0% (11/58). Among the 54 ESCC, a total of 7 genotypes were detected. The total infection rate of HPV was 61.1% (33/54). The positive rate of HPV-16 infection was 63.6% (21/33). The multiple infection rate was 6.1% (2/33). Our result shows that high-risk-type HPV-16 was associated with both cervical cancer and esophageal cancer, which play a role in the high-incidence area in Xinjiang. We hope that our results could point out the direction for the treatment strategy of HPV-associated cancer, cervical cancer, and esophageal cancer and for the application of HPV vaccines in the future.Entities:
Mesh:
Year: 2020 PMID: 33354570 PMCID: PMC7735827 DOI: 10.1155/2020/7926754
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
HPV prevalence in different cervical and esophageal lesions.
| Diagnosis |
| High risk | Low risk | ||||||
|---|---|---|---|---|---|---|---|---|---|
|
| (%) |
| OR | 95% CI |
| (%) |
| ||
| Cervical | |||||||||
| CNOR | 40 | 2 | 5 | 7 | 17.5 | ||||
| CIN | 53 | 37 | 69.8 | <0.001 | 43.94 | 9.44-204.56 | 7 | 13.2 | 0.57 |
| CSCC | 59 | 50 | 84.7 | <0.001 | 105.56 | 21.54-517.19 | 8 | 13.5 | 0.59 |
| Esophageal | |||||||||
| ENOR | 40 | 3 | 7.5 | 5 | 12.5 | ||||
| DYS | 26 | 9 | 34.6 | 0.005 | 6.53 | 1.57-27.21 | 4 | 15.3 | 0.74 |
| ESCC | 54 | 29 | 53.7 | <0.001 | 14.31 | 3.93-52.10 | 4 | 7.4 | 0.41 |
CNOR: cervical normal; CIN: cervical intraepithelial neoplasia; CSCC: cervical squamous cell carcinoma, ENOR: esophageal normal; DYS: esophageal dysplasia; ESCC: esophageal squamous cell carcinoma.
Distribution of HPV genotype in HPV-positive cases.
| Diagnosis |
| High risk | Low risk | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| HPV-16 | HPV18 | HPV56 | HPV59 | HPV33 | HPV45 | HPV6 | HPV11 | HPV43 | ||
|
|
|
|
|
|
|
|
|
| ||
| Cervical | ||||||||||
| CNOR | 9 | 1 (11.1) | 0 (0) | 1 (11.1) | 0 (0) | 0 (0) | 0 (0) | 1 (11.1) | 4 (44.4) | 0 (0) |
| CIN | 44 | 26 (59.1) | 5 (11.4) | 0 (0) | 3 (6.8) | 1 (2.2) | 1 (2.2) | 1 (2.2) | 3 (6.8) | 1 (2.2) |
| CSCC | 58 | 37 (63.7) | 3 (5.2) | 5 (8.6) | 1 (1.7) | 1 (1.7) | 1 (1.7) | 1 (1.7) | 3 (5.2) | 1 (1.7) |
| Esophageal | ||||||||||
| ENOR | 8 | 3 (37.5) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (25) | 1 (12.5) | 1 (12.5) |
| DYS | 13 | 6 (46.2) | 2 (15.4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 3 (23.1) | 0 (0) | 0 (0) |
| ESCC | 33 | 21 (63.6) | 5 (15.2) | 0 (0) | 1 (3.0) | 0 (0) | 1 (3.0) | 3 (9.1) | 1 (3.0) | 0 (0) |
HPV-positive rates of infection types in CSCC and ESCC patients.
| HPV-positive rates (%) | Single-type infection (%) | Multiple-type infection (%) | ||||
|---|---|---|---|---|---|---|
| Co-infection | Tri-infection | Quainfection | Seven infections | |||
| CSCC ( | 98.3 (58/59) | 81.0 (47/58) | 45.5 (5/11) | 18.2 (2/11) | 18.2 (2/11) | 18.2 (2/11) |
| ESCC ( | 59.3 (33/54) | 93.9 (31/33) | 100 (2/2) | 0 | 0 | 0 |
Association between infection with HR-HPV and clinical pathological characteristics of ESCC and CSCC patients.
| Variables | Cases | HPV infection |
|
| |
|---|---|---|---|---|---|
| ( | Positive (%) | Negative (%) | |||
| CSCC patients | |||||
| Age (years) | |||||
| <50 | 12 | 9 (75.0) | 3 (25.0) | 0.363 | 0.547 |
| ≥50 | 47 | 41 (87.2) | 6 (12.8) | ||
| Clinical stage | |||||
| I | 38 | 33 (86.8) | 5 (13.2) | 0.050 | 0.823 |
| II | 21 | 17 (81) | 4 (19) | ||
| Differentiation | |||||
| High | 32 | 27 (84.4) | 5 (15.6) | 5.508 | 0.039 |
| Middle | 12 | 8 (66.7) | 4 (33.3) | ||
| Low | 15 | 15 (100) | 0 (0) | ||
| Lymph node metastasis | |||||
| Positive | 19 | 13 (68.4) | 6 (31.6) | 4.065 | 0.044 |
| Negative | 40 | 37 (92.5) | 3 (7.5) | ||
| ESCC patients | |||||
| Age (years) | |||||
| <50 | 24 | 12 (50.0) | 12 (50.0) | 0.238 | 0.625 |
| ≥50 | 30 | 17 (56.7) | 13 (43.3) | ||
| Gender | |||||
| Male | 31 | 19 (61.3) | 12 (38.7) | 1.685 | 0.194 |
| Female | 23 | 10 (43.5) | 13 (56.5) | ||
| Tumor stage | |||||
| I | 33 | 16 (48) | 17 (52) | 0.930 | 0.335 |
| II | 21 | 13 (61.9) | 8 (38.1) | ||
| Differentiation | |||||
| High | 17 | 8 (47.1) | 9 (52.9) | 1.437 | 0.487 |
| Middle | 22 | 11 (50.0) | 11 (50.0) | ||
| Low | 15 | 10 (66.7) | 5 (33.3) | ||
| Lymph node metastasis | |||||
| Positive | 18 | 11 (61) | 7 (39) | 0.596 | 0.440 |
| Negative | 36 | 18 (50) | 18 (50) | ||